MAHWAH,
N.J., USA, March 21, 2024 /PRNewswire/ -- Stryker
(NYSE: SYK), a leading global medical technology company, announced
today that it has completed the previously announced acquisition of
SERF SAS, a France-based joint
replacement company, from Menix.
"The acquisition of SERF SAS further strengthens our global
portfolio and reinforces our dedication to orthopaedic excellence,"
said Katherine Truppi, President of
Stryker's Joint Replacement division. "We welcome the SERF SAS team
to Stryker and look forward to working together to help advance
product innovation and customer satisfaction."
With a legacy of over 50 years, SERF SAS is recognized by
healthcare professionals worldwide for its innovations in hip
implants, including the invention of the original Dual Mobility
Cup. This acquisition complements Stryker's existing presence in
France and across Europe as well as its global joint replacement
portfolio, allowing Stryker to serve a wider range of patients by
strengthening its implant product line.
"The SERF SAS product portfolio is built on a trusted legacy
within the orthopaedic industry," said Mathieu Badard, Vice President and General
Manager, Stryker's Joint Replacement division, Europe. "We are thrilled to combine our
best-in-class product portfolios and work together to expand our
presence within Europe and
increase patient access to differentiated products for joint
replacement."
Forward-looking statements
This press release contains information that includes or is
based on forward-looking statements within the meaning of the
federal securities law that are subject to various risks and
uncertainties that could cause our actual results to differ
materially from those expressed or implied in such statements. Such
factors include, but are not limited to: weakening of economic
conditions, or the anticipation thereof, that could adversely
affect the level of demand for our products; pricing pressures
generally, including cost-containment measures that could adversely
affect the price of or demand for our products; changes in foreign
currency exchange markets; legislative and regulatory actions;
unanticipated issues arising in connection with clinical studies
and otherwise that affect United States Food and Drug
Administration approval of new products; inflationary pressures;
increased interest rates; supply chain disruptions; changes in
reimbursement levels from third-party payors; a significant
increase in product liability claims; the ultimate total cost with
respect to recall-related matters; the impact of investigative and
legal proceedings and compliance risks; resolution of tax audits;
changes in tax laws and regulations; the impact of federal
legislation to reform the United
States healthcare system; costs to comply with medical
device regulations; changes in financial markets; changes in our
credit ratings; changes in the competitive environment; our ability
to integrate and realize the anticipated benefits of acquisitions
in full or at all or within the expected timeframes; our ability to
realize anticipated cost savings; potential negative impacts
resulting from environmental, social and governance (ESG) and
sustainability related matters; the impact on our operations and
financial results of any public health emergency and any related
policies and actions by governments or other third parties; and
breaches or failures of our or our vendors' information technology
systems or products, including by cyber-attack, data leakage,
unauthorized access or theft. Additional information concerning
these, and other factors is contained in our filings with the
United States Securities and Exchange Commission, including our
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We
disclaim any intention or obligation to publicly update or revise
any forward-looking statement to reflect any change in our
expectations or in events, conditions or circumstances on which
those expectations may be based, or that affect the likelihood that
actual results will differ from those contained in the
forward-looking statements.
About Stryker
Stryker is a global leader in medical
technologies and, together with its customers, is driven to make
healthcare better. The company offers innovative products and
services in MedSurg, Neurotechnology, Orthopaedics and Spine that
help improve patient and healthcare outcomes. Alongside its
customers around the world, Stryker impacts more than 150 million
patients annually. More information is available at
www.stryker.com.
About Menix
Menix comprises cutting-edge technological
industries in the orthopaedic (primarily hip and knee) and dental
sectors, as well as 3D digital solutions. In the field of
orthopaedics, Menix enjoys a leadership position on the dual
mobility and first intention stem markets in France.
About SERF
SAS
SERF SAS is a French company
that develops, manufactures, and sells a range of large joint
replacement products on an international basis. Since its founding,
SERF SAS has developed numerous innovative concepts, including the
invention of the original Dual Mobility Cup. SERF SAS's main office
is based in Décines-Charpieu, France.
Media contact
Stryker, Joint Replacement
Niamh Grano
Sr. Communications Manager
niamh.grano@stryker.com
+1 201.831.5589
View original content to download
multimedia:https://www.prnewswire.com/news-releases/stryker-completes-acquisition-of-serf-sas-302095203.html
SOURCE Stryker